Recursion Pharmaceuticals, Inc.
RXRX
$3.05
-$0.10-3.18%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -8.68% | 33.36% | 5.61% | 15.11% | -13.18% |
| Total Depreciation and Amortization | 1.00% | -7.44% | -11.77% | 23.37% | 49.26% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -23.06% | -36.41% | 37.47% | -36.06% | 7.17% |
| Change in Net Operating Assets | -173.06% | 140.63% | -174.80% | 700.70% | -116.02% |
| Cash from Operations | -76.03% | 60.74% | -53.58% | 42.09% | -14.32% |
| Capital Expenditure | 79.26% | -411.93% | 92.29% | -71.94% | -41.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | 100.00% | -- |
| Other Investing Activities | -- | 100.00% | 13.24% | -165.80% | -185.71% |
| Cash from Investing | 72.83% | 51.20% | 56.11% | 20.11% | -102.64% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.89% | -1.88% | -2.06% | -1.81% | 2.57% |
| Issuance of Common Stock | -- | -47.06% | 146.70% | 150.45% | 222.01% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -293.55% | -- |
| Cash from Financing | -102.63% | -47.48% | 157.36% | 140.97% | 280.93% |
| Foreign Exchange rate Adjustments | -283.61% | 11.66% | -79.81% | 91.50% | 239.20% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -202.26% | -34.90% | 439.94% | 126.30% | -156.14% |